In today’s Pharmaceutical Executive Daily, Pfizer discloses its 2026 revenue expectations, a bipartisan group of House ...

Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them.

When President Donald Trump declared in May that he wanted drug companies to voluntarily cut their prices, few pharmaceutical ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

If pharmaceutical drug patents are an hourglass turned over on the day of approval - with the approaching loss of exclusivity ...

Today, the New York State Emerging Technology Advisory Board (ETAB) released its final report of recommendations to Governor ...

The Trump administration on Friday announced deals with nine drugmakers aimed at lowering pharmaceutical prices, bringing its total number of drug-pricing agreements to 14.

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

We recently published 12 Stocks on Jim Cramer’s Radar . Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...